^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CXCL6 (C-X-C Motif Chemokine Ligand 6)

    i
    Other names: CXCL6, C-X-C Motif Chemokine Ligand 6, GCP-2, CKA-3, Granulocyte Chemotactic Protein 2, SCYB6, Small Inducible Cytokine Subfamily B (Cys-X-Cys), Member 6 (Granulocyte Chemotactic Protein 2), Chemokine (C-X-C Motif) Ligand 6 (Granulocyte Chemotactic Protein 2), Small-Inducible Cytokine B6, C-X-C Motif Chemokine 6, Chemokine Alpha 3, GCP2, Small Inducible Cytokine Subfamily B (Cys-X-Cys), Member B, Chemokine (C-X-C Motif) Ligand 6
    27d
    Human and viral chemokines differentially modulate G protein signaling, β-arrestin recruitment and chemotaxis mediated by the viral G protein-coupled receptor ORF74. (PubMed, Cell Commun Signal)
    Our comprehensive profiling of ORF74 chemokine ligands reveals ligand-dependent activation of canonical signaling pathways, including calcium mobilization, β-arrestin recruitment and chemotaxis. We confirm that ORF74 exhibits constitutive β-arrestin recruitment and, upon co-expression with CXCR4, is able to modulate CXCL12-CXCR4-mediated cell migration. These data highlight the complex chemokine-ORF74 interplay and will contribute to a better understanding of KSHV infection and pathology through multiple ORF74-dependent mechanisms.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    29d
    Causal effect between systemic inflammatory cytokines and osteoporotic pathological fractures: A bidirectional Mendelian randomization study. (PubMed, Medicine (Baltimore))
    This study unveils a complex bidirectional relationship between circulating inflammatory factors and osteoporotic pathological fractures. These findings provide novel insights into the pathogenesis of osteoporosis and offer important clues for potential preventive, diagnostic, and therapeutic strategies.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL10 (Interleukin 10) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • TGFB1 (Transforming Growth Factor Beta 1) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • TSLP (Thymic Stromal Lymphopoietin)
    1m
    The CXCR1 as a putative marker for cancer stem cell-like phenotypes in chemotherapy-resistant pancreatic ductal adenocarcinoma. (PubMed, Am J Cancer Res)
    Combination treatment with gemcitabine and Navarixin, a CXCR1 inhibitor, significantly reduced expression of CXCR1, CXCL6, and CSC/EMT markers in vitro. In vivo, tumors treated with the combination therapy showed markedly lower CXCR1 and CXCL6 expression than other treatment groups. These findings indicate that the CXCR1 axis supports CSC maintenance in PDAC, and that co-targeting CSC and non-CSC populations may improve therapeutic outcomes.
    Journal
    |
    CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCR1 (Chemokine (C-X-C motif) receptor 1)
    |
    gemcitabine • navarixin (MK-7123)
    1m
    Inflammatory proteins in pre-diagnosis versus at-diagnosis samples associated with differentiated thyroid cancer. (PubMed, Int J Cancer)
    Overall, we found a difference in inflammatory proteins negatively associated with thyroid cancer in the at- versus the pre-diagnosis group. These findings highlight that inflammation potentially has a dual role in thyroid carcinogenesis.
    Journal
    |
    CCL20 (C-C Motif Chemokine Ligand 20) • FGF21 (Fibroblast Growth Factor 21) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL7 (Interleukin 7) • MMP1 (Matrix metallopeptidase 1) • TSLP (Thymic Stromal Lymphopoietin)
    1m
    Circulating inflammatory proteins and osteomyelitis: A bidirectional Mendelian randomization and colocalization analysis. (PubMed, Medicine (Baltimore))
    This study identified several CIPs - including TNF-β, osteoprotegerin, and adenosine deaminase - as potentially causal in OM development. These findings highlight promising targets for future immunomodulatory therapies aimed at preventing or mitigating osteomyelitis.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CCL19 (C-C Motif Chemokine Ligand 19) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL15 (Interleukin 15) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B)
    2ms
    Dietary quercetin supplementation alleviates claw lesions in dairy cows by modulating the PI3K/Akt and NF-κB signaling pathways. (PubMed, BMC Vet Res)
    In conclusion, our findings indicate that dietary quercetin supplementation alleviates claw lesions and decreases the inflammatory response of lamellar tissues in dairy cows by modulating the PI3K/Akt and NF-κB signaling pathways. These results suggest that quercetin may serve as a natural anti-inflammatory candidate for the management of claw lesions in dairy cattle, offering new insights to improve hoof health and animal welfare in modern dairy pastures.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL1B (Interleukin 1, beta) • NFKBIA (NFKB Inhibitor Alpha 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    2ms
    Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma. (PubMed, Gut)
    Activation of the galectin-4/LDHA/HIF-1α and CXCL6 axis plays a pivotal role in ATZ/BVZ therapy resistance. Galectin-4 serves as a promising therapeutic target to improve immunotherapy efficacy and an effective predictive biomarker for immunotherapy response in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LDHA (Lactate dehydrogenase A) • CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • LGALS4 (Galectin 4) • TRIM28 (Tripartite Motif Containing 28)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    3ms
    Angiogenesis-Related Genes Predict Outcomes and Immune Traits in Skin Melanoma. (PubMed, Int J Mol Sci)
    The study underscores the prognostic relevance of ARGs in skin melanoma and their contribution to tumor immunity. Overall, our findings expand our understanding of melanoma immunogenetics, suggesting the use of angiogenesis-related genes not merely as vascular regulators, but also as immune modulators.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • COL3A1 (Collagen Type III Alpha 1 Chain) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • COL5A2 (Collagen Type V Alpha 2 Chain) • PTK2 (Protein Tyrosine Kinase 2) • S100A4 (S100 calcium binding protein A4)
    3ms
    Investigating bidirectional causality between prostate cancer and inflammatory factors: A 2-sample Mendelian randomization analysis. (PubMed, Medicine (Baltimore))
    Specifically, the results suggested that Flt3L and MCP4 may be risk factors for PCa, whereas MCP2 may be a favorable factor for PCa. Conversely, adenosine deaminase, axin-1, C-X-C motif chemokine ligand 6, IL-24, IL-33, and Flt3L were involved in the downstream of PCa progression.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • AXIN1 (Axin 1) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand) • IL33 (Interleukin 33)
    5ms
    Effect and mechanism of Bufei Decoction on improving Klebsiella pneumoniae pneumonia in rats by regulating IL-17 signaling pathway (PubMed, Zhongguo Zhong Yao Za Zhi)
    SD rats were randomly divided into the control group, model group, Bufei Decoction low-dose group(6.68 g·kg~(-1)·d~(-1)), Bufei Decoction high-dose group(13.36 g·kg~(-1)·d~(-1)), and dexamethasone group(1.04 mg·kg~(-1)·d~(-1)), with 10 rats in each group...In conclusion, Bufei Decoction can effectively improve lung tissue damage and reduce inflammation in rats with K. pneumoniae. The mechanism may involve the regulation of the IL-17 signaling pathway and the reduction of apoptosis.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL1B (Interleukin 1, beta) • TRAF6 (TNF Receptor Associated Factor 6)
    |
    dexamethasone
    5ms
    Transcriptomic profiling of PBMCs from mammary tumor dogs reveals two distinct immune states. (PubMed, Am J Cancer Res)
    Notably, CD7, CXCL6, FASN, FLT3LG, LTB, and TNFRSF18 were significantly downregulated, marking a potential transcriptomic signature of systemic immune impairment. These findings suggest that immune dysfunction in the PI group is not solely attributable to conventional immune suppression but rather to a diminished immune activation state driven by reduced TNFRSF gene expression.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CD27 (CD27 Molecule) • TNFRSF14 (TNF Receptor Superfamily Member 14) • IL18 (Interleukin 18) • CD7 (CD7 Molecule) • FAS (Fas cell surface death receptor) • FASN (Fatty acid synthase) • TNFRSF18 (TNF Receptor Superfamily Member 18) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL7 (Interleukin 7) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)